분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2014-11-26 16:14:02 , Hit : 1291
 EMA panel recommends approval of DAA regimen for patients with HCV

November 21, 2014


The European Committee for Medicinal Products for Human Use, or CHMP, granted a positive opinion for the recommendation of Viekirax plus Exviera, with or without ribavirin, for the treatment of chronic hepatitis C genotype 1 and 4 infection, according to a press release.

  

See Also
EMA committee recommends Harvoni to treat HCV ...
Dynavax withdraws European marketing application for ...
PEARL-II, III: High SVR rates met in HCV genotype 1b patients ...
  
Featured

Liver Meeting 2014
ACG 2014
EASL 2014

Highlights from The Liver Meeting 2014
Highlights from ACG 2014
Highlights from DDW 2014
Highlights from EASL 2014

The Viekirax (omitasvir/paritaprevir/ritonavir, AbbVie) and exviera (dasabuvir, AbbVie) combination was looked upon favorably based on data from multiple phase 3 studies — SAPPHIRE-I, SAPPHIRE-II, PEARL-II, PEARL-III, PEARL-IV and TURQUOISE-II. The CHMP’s recommendation will be addressed by the European Commission, which has the authority to approve the drug for the European Union. More than 2,300 patients have been included in the studies with the direct-acting antiviral regimen, and the treatment has been generally well tolerated.

“The CHMP positive opinions mark an important milestone in our HCV development program and recognizes the potential our treatment brings to people in Europe living with this chronic condition,” Michael Severino, MD, executive vice president of research and development and chief scientific officer of AbbVie, said in the press release. “Our treatment has been developed with the goal of achieving high cure rates in a broad range of genotype 1 patients with low rates of discontinuation and relapse.”

The all-oral, interferon-free regimen consists of a fixed-dose combination of the protease inhibitor ritonavir, at 100 mg/150 mg, co-formulated with 25 mg ombitasvir, administered once daily, along with 250 mg dasabuvir with or without ribavirin, administered twice daily. The European Medicines Agency (EMA) has granted accelerated assessment for the combination treatment. If approved, the regimen will be available for marketing in all 28 European Union member states.

AbbVie submitted a new drug application for the investigational treatment to the FDA in April. The FDA assigned the treatment breakthrough therapy designation in May 2013, granting it priority review.







1027   아수라장 속에서 탄생한 생명  이성욱 2014/12/17 1250
1026   유전자 넉아웃을 보상하는 또 다른 유전자  이성욱 2015/07/30 1253
1025   CRISPR-Cas9 Inhibitors Found in Metagenomics Study  이성욱 2019/02/07 1254
1024   역풍 맞은 사이언스 논문 - 암은 대부분 운이 나빠 발생한다?  이성욱 2015/01/21 1255
1023   생물안전 규제를 우회하는 유전체교정 기법: 외부 DNA 없는 CRISPR  이성욱 2015/10/21 1270
1022   세균이 위협을 기억하는데 도움을 주는 바이러스 절단 효소  이성욱 2015/02/25 1274
1021   Genzyme, Voyager Launch Up-to-$845M Gene Therapy Collaboration  이성욱 2015/02/14 1277
1020   환기불량이 한국에서 MERS 슈퍼전파를 일으켰을까?  이성욱 2015/06/09 1279
1019   술의 역사: 영장류가 진화한 것은 알코올 섭취능력 때문?  이성욱 2014/12/04 1285
1018   에볼라에 대한 반응과 유전적 요인  이성욱 2014/11/04 1288
  EMA panel recommends approval of DAA regimen for patients with HCV  이성욱 2014/11/26 1291
1016   Novartis Extends Deal to Use SomaLogic Proteomics Technology  이성욱 2014/10/23 1296
1015   남성 동성애와 관련된 후성유전학 태그  이성욱 2015/10/12 1302
1014   암확산을 중단시키는 박테리아 소통시스템  이성욱 2014/09/29 1305
1013   Roche says to buy Danish Santaris for up to $450 million  이성욱 2014/08/06 1308
1012   CRISPR Turbocharges CAR T Cells, Boosts Cancer Immunotherapy  이성욱 2017/02/24 1309
1011   STAP세포논문철회에서 새롭게 밝혀진 사실들  이성욱 2014/09/15 1311
1010   CVS Gives Preferred Status to Gilead’s Hepatitis C Drugs  이성욱 2015/01/07 1312
1009   단일 돌연변이가 망막 종양으로 이어지는 이유  이성욱 2014/09/29 1328
1008   Genetically 'edited' fruit could soon hit supermarket shelves  이성욱 2014/08/15 1331

[이전 10개] [1]..[11][12] 13 [14][15][16][17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2022 Zeroboard / skin by ROBIN